The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Arcus Biosciences Inc (NYSE: RCUS) closed at $15.71 down -4.67% from its previous closing price of $16.48. In other words, the price has decreased by -$4.67 from its previous closing price. On the day, 0.65 million shares were traded. RCUS stock price reached its highest trading level at $16.57 during the session, while it also had its lowest trading level at $15.7.
Ratios:
For a deeper understanding of Arcus Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.14 and its Current Ratio is at 5.14. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’24 when Azoy Alexander sold 1,357 shares for $14.97 per share. The transaction valued at 20,314 led to the insider holds 19,070 shares of the business.
Jarrett Jennifer sold 11,551 shares of RCUS for $202,720 on Mar 27 ’24. The Chief Operating Officer now owns 215,253 shares after completing the transaction at $17.55 per share. On Mar 18 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 13,449 shares for $17.92 each. As a result, the insider received 240,941 and left with 226,804 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1436326144 and an Enterprise Value of 498326112. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.82 while its Price-to-Book (P/B) ratio in mrq is 2.26. Its current Enterprise Value per Revenue stands at 2.018 whereas that against EBITDA is -1.888.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $20.48, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is -1.96%, while the 200-Day Moving Average is calculated to be -4.81%.
Shares Statistics:
For the past three months, RCUS has traded an average of 651.84K shares per day and 642130 over the past ten days. A total of 75.50M shares are outstanding, with a floating share count of 48.65M. Insiders hold about 46.79% of the company’s shares, while institutions hold 53.05% stake in the company. Shares short for RCUS as of 1724976000 were 6735848 with a Short Ratio of 10.33, compared to 1722384000 on 6620446. Therefore, it implies a Short% of Shares Outstanding of 6735848 and a Short% of Float of 15.21.
